Detalhe da pesquisa
1.
Ruxolitinib for Glucocorticoid-Refractory Chronic Graft-versus-Host Disease.
N Engl J Med
; 385(3): 228-238, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34260836
2.
Safety and efficacy of parsaclisib in combination with obinutuzumab and bendamustine in patients with relapsed or refractory follicular lymphoma (CITADEL-102): A phase 1 study.
Hematol Oncol
; 41(5): 848-857, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37496298
3.
Inhibition of cytokine signaling by ruxolitinib and implications for COVID-19 treatment.
Clin Immunol
; 218: 108517, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32585295
4.
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Lancet Oncol
; 15(9): 975-85, 2014 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-24974051
5.
Safety and efficacy of parsaclisib in combination with rituximab, bendamustine + rituximab, or ibrutinib in patients with previously treated B-cell lymphoma: analysis of a phase 1 dose-finding study (CITADEL112).
Leuk Lymphoma
; : 1-11, 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598516
6.
JAK inhibitors and COVID-19.
J Immunother Cancer
; 10(4)2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35459733
7.
Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Rheumatol
; 4(5): e351-e361, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35368384
8.
Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial.
Lancet Oncol
; 11(7): 619-26, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-20570559
9.
Baseline vascular endothelial growth factor concentration as a potential predictive marker of benefit from vandetanib in non-small cell lung cancer.
Clin Cancer Res
; 15(10): 3600-9, 2009 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-19447868
10.
Design of Clinical Trials Evaluating Ruxolitinib, a JAK1/JAK2 Inhibitor, for Treatment of COVID-19-Associated Cytokine Storm.
Dela J Public Health
; 6(2): 50-54, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-34467111
11.
A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.
Blood Adv
; 4(8): 1656-1669, 2020 04 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-32324888
12.
Th1 cytokines, programmed cell death, and alloreactive T cell clone size in transplant tolerance.
J Clin Invest
; 109(11): 1471-9, 2002 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-12045261
13.
Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
J Hematol Oncol
; 10(1): 156, 2017 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-28962635
14.
Magnetic resonance imaging measurements of the response of murine and human tumors to the vascular-targeting agent ZD6126.
Clin Cancer Res
; 10(11): 3650-7, 2004 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15173071
15.
Vandetanib Versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR).
J Clin Oncol
; 30(10): 1114-21, 2012 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22370318
16.
Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
J Clin Oncol
; 30(2): 134-41, 2012 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-22025146
17.
Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial.
J Clin Oncol
; 29(8): 1067-74, 2011 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21282537
18.
Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer.
J Clin Oncol
; 29(8): 1059-66, 2011 Mar 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-21282542
19.
Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Clin Pharmacokinet
; 49(9): 607-18, 2010 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-20690783
20.
Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer.
J Clin Oncol
; 28(2): 193-201, 2010 Jan 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-19949019